CVE-2019-15933 in Solismed
Summary
by MITRE
Intesync Solismed 3.3sp has SQL Injection.
If you want to get best quality of vulnerability data, you may have to visit VulDB.
Analysis
by VulDB Data Team • 03/11/2024
The CVE-2019-15933 vulnerability represents a critical SQL injection flaw discovered in the Intesync Solismed 3.3sp medical device software system. This vulnerability exists within the authentication and data processing mechanisms of the platform, potentially allowing unauthorized users to execute malicious SQL commands against the underlying database infrastructure. The affected system operates within healthcare environments where sensitive patient data and medical records are stored, making this vulnerability particularly concerning from a cybersecurity perspective. The vulnerability stems from improper input validation and sanitization of user-supplied data within the application's web interface and API endpoints, creating pathways for attackers to manipulate database queries through crafted input parameters.
The technical exploitation of this SQL injection vulnerability occurs when the application fails to properly escape or validate user input before incorporating it into database queries. Attackers can leverage this flaw by submitting malicious SQL payloads through various input fields, including login forms, search parameters, or API request bodies. The vulnerability allows for unauthorized database access, enabling threat actors to extract sensitive information, modify medical records, or potentially escalate privileges within the system. This type of vulnerability aligns with CWE-89 which specifically addresses SQL injection flaws in software applications, and represents a common vector for data breaches in healthcare environments where regulatory compliance requirements such as HIPAA mandate strict protection of patient information. The attack surface is particularly broad given that the vulnerability affects a medical device platform that likely handles multiple user roles including healthcare professionals, administrators, and potentially patients accessing telemedicine services.
The operational impact of CVE-2019-15933 extends beyond immediate data compromise to encompass significant business and regulatory risks. Healthcare organizations utilizing Intesync Solismed 3.3sp systems face potential exposure of protected health information including patient medical histories, treatment records, and personal identifiers. The vulnerability could enable attackers to gain unauthorized access to critical medical data, potentially leading to identity theft, insurance fraud, or even life-threatening situations if patient records are altered or corrupted. From an attacker perspective, this vulnerability maps to several ATT&CK techniques including T1190 for exploitation of vulnerabilities, T1071.004 for application layer protocol usage, and T1005 for data from local system. The attack chain typically involves reconnaissance to identify vulnerable input points, crafting of malicious SQL payloads, and subsequent exploitation to achieve unauthorized database access or privilege escalation.
Mitigation strategies for this vulnerability require immediate implementation of input validation and parameterized query approaches to prevent SQL injection attacks. Organizations should deploy web application firewalls and database activity monitoring solutions to detect and prevent malicious SQL injection attempts. The affected vendor should provide immediate security patches or firmware updates to address the vulnerability, while system administrators must implement proper access controls and database user privilege management. Additional protective measures include regular security assessments, input sanitization protocols, and comprehensive network segmentation to limit the potential impact of successful exploitation. Compliance with industry standards such as NIST SP 800-53 and ISO 27001 should be maintained to ensure proper security controls are in place. The vulnerability highlights the critical need for continuous security monitoring and regular vulnerability assessments in medical device environments where the stakes for data protection are exceptionally high.